726. Safety of MenB-FHbp (Bivalent rLP2086), a Meningococcal Serogroup B Vaccine, in Young Adults: Results from a Phase 3 Trial
Session: Poster Abstract Session: Vaccines: Adolescent HPV and Meningococcal
Thursday, October 27, 2016
Room: Poster Hall
Posters
  • 726.Ostergaard.pdf (998.9 kB)
  • Background: MenB-FHbp (bivalent rLP2086) was the first vaccine licensed in the US through an accelerated approval process to prevent invasive meningococcal serogroup B (MnB) disease in individuals aged 10–25 years. Confirmatory immunogenicity and safety studies have been completed, with a large proportion of subjects having been enrolled in the United States. We present data from the safety evaluations of US subjects enrolled in one of 3 large phase 3 studies.

    Methods: Healthy subjects aged 18 to <26 years were randomized to MenB-FHbp or saline at 0, 2, and 6 months. Safety variables, including local, systemic reactions and antipyretic use within 7 days after vaccination, and unsolicited adverse events (AEs), including immediate AEs, medically-attended AEs (MAEs), SAEs, and newly diagnosed chronic medical conditions (NDCMCs), were assessed.

    Results: 2471 and 822 subjects received MenB-FHbp or saline, respectively; 1644 were from the US (MenB-FHbp, n=1232; saline, n=412). Local and systemic reactions were more common with MenB-FHbp, mostly mild or moderate in severity, and more frequent after the first vaccination. Injection-site pain (83.7%) and fatigue (59.0%) were the most common local and systemic reactions with MenB-FHbp, respectively (Figure). 4.1% and 1.0% of MenB-FHbp and control recipients reported fever ≥38°C (Figure) and 17.6% and 7.8%, respectively, used antipyretics. One MenB-FHbp recipient reported fever >40.0°C which lasted 1 day. Worsening of severity of local and systemic events with subsequent vaccinations was not observed. Few SAEs were reported overall among US subjects. Similar rates of AEs, SAEs MAEs, and NDCMC were reported between groups; Table).

    Conclusion: MenB-FHbp was safe and tolerable among US adolescents. Results were consistent with the safety profile observed in the global study.

    Lars Østergaard, MD, PhD1, Brian J. Ward, MD2, Johannes F. Beeslaar, MD3, Joseph J. Eiden, MD, PhD4, Kathrin U. Jansen, PhD4, Judith Absalon, MD, MPH4, Laura J. York, PhD5, David Radley, MS6, Jean-Louis Prégaldien, MS7, Nina Breinholt Staerke, MD1 and John L. Perez, MD, MA6, (1)Arhus Universitetshospital, Skejby, Aarhus C, Denmark, (2)Research Institute of the McGill University Health Center, Montreal, QC, Canada, (3)Pfizer Ltd, Walton Oaks, United Kingdom, (4)Pfizer Vaccine Research, Pearl River, NY, (5)Pfizer Medical Development and Scientific Affairs, Collegeville, PA, (6)Pfizer Vaccine Research, Collegeville, PA, (7)Pfizer Vaccine Research, Brussels, Belgium

    Disclosures:

    L. Østergaard, None

    B. J. Ward, None

    J. F. Beeslaar, Pfizer Ltd: Employee and Shareholder , Salary and Stock, Stock options, and long term projections

    J. J. Eiden, Pfizer, Inc: Employee , Salary

    K. U. Jansen, Pfizer, Inc: Employee and Shareholder , Salary

    J. Absalon, Pfizer, Inc: Employee , Salary

    L. J. York, Pfizer, Inc: Employee , Salary

    D. Radley, Pfizer, Inc: Employee and Shareholder , Salary

    J. L. Prégaldien, Pfizer Ltd: Employee , Salary

    N. Breinholt Staerke, Pfizer, Inc: Investigator , Study Sponsored by Pfizer

    J. L. Perez, Pfizer, Inc: Employee , Salary

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.